Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesTeva Announces Approval And Launch Of Generic Urso 250 And Urso Forte
Teva Pharmaceutical Industries, 05/15/09
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application for Ursodiol Tablets USP, 250 mg and 500 mg. Teva's Ursodiol Tablets are the AB-rated generic equivalents of Axcan's Urso 250 and Urso Forte, which are indicated for treatment of patients with primary biliary cirrhosis. Shipment of this product has commenced.
Today in Drug Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
Expert Opinion in Pharmacotherapy, 12/09/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
Recombinant Human Erythropoietin, Epogin Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09
Today in Drug/Product Alerts...keeping you current
Receive free subspecialty "5-minute updates" via email
Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
Expert Opinion in Pharmacotherapy, 12/09/09
Synthon announces European approvals for Raloxifene
Synthon, 12/08/09
Recombinant Human Erythropoietin, Epogin Injection
Application for Approval of Additional Indication of Chemotherapy-Induced Anemia
Chugai Pharmaceutical Co., 12/08/09
Sponsor
Article Search
Sponsor